

Performance criteria or "quality specifications"

Gunnar Nordin

Dubrovnik Course in Zagreb 2015



Do we need performance specifications?





Do we need <u>common</u> performance specifications?

- Criteria for the use of a test in a specific clinical setting
- Criteria to share common reference interval and decision levels
- Criteria for acceptable performance in EQA



The Stockholm consensus

CONSENSUS STATEMENT*

The main outcome of the Conference was agreement that the following hierarchy of models should be applied to set analytical quality specifications.

- 1. Evaluation of the effect of analytical performance on clinical outcomes in specific clinical settings
- Evaluation of the effect of analytical performance on clinical decisions in general:
 - a. Data based on components of biological variation
 - b. Data based on analysis of clinicians' opinions
- 3. Published professional recommendations
 - a. From national and international expert bodies
 - b. From expert local groups or individuals
- 4. Performance goals set by
 - a. Regulatory bodies
 - b. Organizers of External Quality Assessment (EQA) schemes
- 5. Goals based on the current state of the art
 - a. As demonstrated by data from EQA or Proficiency Testing scheme
 - b. As found in current publications on methodology.



European Commission Joint Research Centre

IRMM

Institute for Reference Materials and Measurements



1st EFLM Strategic Conference
Defining analytical
performance goals
15 years after the
Stockholm Conference

8th CIRME International Scientific Meeting

Milan (IT) 24-25 November 2014









Consensus Statement

Sverre Sandberg*, Callum G. Fraser, Andrea Rita Horvath, Rob Jansen, Graham Jones, Wytze Oosterhuis, Per Hyltoft Petersen, Heinz Schimmel, Ken Sikaris and Mauro Panteghini

Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine

The 5+ level hierarchy replaced by a 3 level hierarchy:

- 1. Evidence
- 2. Biology
- 3. Technique



What type of evidence?

Clinical outcome

- Mortaility
- Time to treatment
- Financial benefits

Few studies

- Troponin test for diagnosis of acute coronary syndrome
- Rapid test for Strep A, to reduce the prescription of antibiotics
- Blood glucose for the monitoring of diabetes, and some more



What type of evidence?

Clinical expectations are also evidence

The experienced clinician "knows" the performance of a test.

Opinion Paper

Geir Thue and Sverre Sandberg*

Analytical performance specifications based on how clinicians use laboratory tests. Experiences from a post-analytical external quality assessment programme




What biological variation?

Biological variation

- Between individual
- Within individual



What biological variation





Biological variation - terminology

Table 1. Terms and symbols most commonly used to define thecomponent of BV applicable to individuals and groups.					
Term	Frequency of term	Symbols	Frequency of symbol		
Applicable to individuals		\frown			
Within-subject biological variation	18	cv,	35		
Intraindividual biological variation	11	CVw	8		
Intraindividual variation	11	CV	7		
Intraindividual variation	10	CVw	6		
Within-subject variation	9	CVw	6		
Within-subject coefficient of variation	5	CV	6		
Intraindividual variability	4	CV _{within-subject}	3		
Within-person biological variation	4	CV _{blological}	3		
Within-person variation	4	CVb	3		
Intraindividual biological variation	3				
Intraindividual CV	3				
Within-subject CV	3				
Within-subject biological variation	3				
Applicable to groups	\frown				
Between-subject biological variation	16	CV _G	29		
Interindividual variation	14	CVg	7		
Between-subject variation	7	CVg	5		
Interindividual biological variation	5	CVb	4		
Interindividual CV	5	CVb	2		
Interindividual variability	5				
Between-person variation	4				
Between-subject coefficient of variation	4				
Interindividual variation	4				

IS

Simundic et al, 2015

What biological variation?

Anna Carobene*

Reliability of biological variation data available in an online database: need for improvement

DE GRUYTER

Clin Chem Lab Med 2015; 53(6): 879-885

Opinion Paper

William A. Bartlett*, Federica Braga, Anna Carobene, Abdurrahman Coşkun, Richard Prusa, Pilar Fernandez-Calle, Thomas Røraas, Neils Jonker and Sverre Sandberg, on behalf of the Biological Variation Working Group, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

A checklist for critical appraisal of studies of biological variation



- T			
	Length of study	3.4 (C)	Length of the study periods should be clearly identified.
	Sampling	3.5 (C)	Sampling protocols (e.g., subject preparation, sampling conditions) that minimise pre-analytical variation should be adequately described to enable transportability of the data [25]. Numbers of samples taken should be sufficient to deliver the required power to the study [25, 26].
	Samples	3.6 (C)	Recorded details should include the beginning and end date of the study and timings of sampling. Sampling conditions and sample type should be described in detail. Pre-analytical storage conditions of samples should be described.
	Conditions for analysis of samples	3.7 (C)	A description of conditions under which the samples were analysed. Analytical protocols should be designed to minimise sources of analytical variation (Optimal Conditions Precision) [24].
	Data analysis	4	Data analysis techniques should be described. The power of the study to identify indices of biological variation should be calculated and presented ^b [26].
	Outlier analysis	4.1 (C)	Outliers should be excluded from the final analysis of the data. Test for outliers should be applied to all levels of data (between replicate analysis, between samples within subject, between subjects) [25]. The numbers of outliers and reasons for their exclusion must be given.
	Heterogeneity of variance	4.2 (C)	Subjects with outlying within subject variance should be rejected from calculations used to determine an estimate of common true variance. The numbers of outliers and reasons for their exclusion must be given ⁶ .
	Statistical methods described and appropriate	4.3 (C)	Statistical methods used should be appropriately identified, fit for purpose and referenced. Data that do not conform to a normal distribution should be appropriately transformed [25].
	Results	5	Unified terminology [13] should be used and appropriately defined metadata clearly presented to enable understanding and transportation of the data through time and across health care systems.
	Terminology	5.1 (D)	Terms and symbols should be used to describe biological variation should conform standards identified by Simundic et al. [13].
	Results clearly presented and managed	5.2 (D)	Biological variation data, with derived indices, should be tabulated in a format that enables extraction of the key data unambiguously associated with a minimum data set to enable transportability of the data. Power of the study and confidence limits around estimates of
5			biological variation should be presented [26]. The results section should clearly identify the results of outlier analysis undertaken and confirm homogeneity of the data sets. If data are stratified the variables used to enable this should be clearly
			characterised.

Bartlett et al, 2015

What biological variation?

Biological variation

- Between individual
- Within individual

Anything else?

- Matrix effects
- Sample specific error components



What biological variation?

- If the within-subject variation is very heterogenic, a common figure that is representative for a group of individuals can not be found.
- Performance specification can not be based on data unless representative for the target patient population.
- The matrix effect, or sample specific error component, must be considered.



What technique?

"State of the art" quality?

The imprecision should be less than half of the within-subject biological variation (CV_{bw}) or the total imprecision should be less than the imprecision that can be achieved by the better 50% of laboratories in the external quality schemes.

Quality specifications as stated by an EQA oragnisation

The best possible quality?





Task and finish group "Allocation of laboratory tests to different models for performance specifications" (TFG-DM).



TFG - DM

- Terms of Reference: To allocate different tests to different models recognized in the Strategic Conference Consensus Statement and to give an overview and a reason for why tests are allocated to the different models.
- Deliverable: To produce a list of laboratory tests allocated to the different performance specifications (starting with the most common) to be put on the EFLM website. To publish a paper describing the rationale behind listing the different tests in the different model groups.



TFG – DM composition

Chair Ferruccio Ceriotti - Italy

Members

George Klee - USA Pilar Fernández-Calle - Spain Gunnar Nordin - Sweden Mauro Panteghini - Italy Sverre Sandberg - Norway Thomas Streichert - Germany Joan-Lluis Vives Corrons - Spain



1) Possible criteria

- The measurand has a central role in diagnosis and monitoring of a specific disease ⇒ outcome criteria;
- 2. The measurand has a high homeostatic control \Rightarrow BV criteria;
- Neither central diagnostic role nor sufficient homeostatic control ⇒ state-ofthe-art.

One or several different performance specifications for each test?

Different specification for POCT and hospital use of a test?

Different specification due to the intended use of a test?

- Screening versus confirmation tests?
- Use for monitoring, diagnosis or something else?

Yes, we need one performance specification for each intended use!



Equalis performance specifications ("quality goals")

Different specifications for different materials

expertgrupp för Allmän

Tabell 1. Allmän klinisk kemi. Kvalitetsmålen är uppställda klinisk kemi.

Storhet	Maximal avvikeise (±%)		Maximal avvikelse i	Kommentar
	Modifierat serum	Naturligt serum	absoluta tal vid referensintervallets övre gräns	
P—ALAT	12	12+	0,13 µkat/L	
P—Albumin	5	5	2,4 g/L	
P—ALP	12	12	0,22 µkat/L	
P—Amylas	12	12	0,24 µkat/L	
P—Pankreasamylas	12	12	-Ŧ	
P—ASAT	12	12	0,09 µkat/L	
P—Bilirubin	12	12	3,0 µmol/L	
P—Bilirubin, konjugerat	12	12	-Ŧ	
P—Calcium	3	3	0,08 mmol/L	
Р—СК	12	12	0,81 µkat/L	
P—Fosfat	6	6	0,10 mmol/L	
P—Glukos	10	10	-	
P—GT	12	12	0,23 µkat/L	
P—HDL-kolesterol	10	10	0,27 mmol/L	
P—Järn	12	12	4,1 µmol/L	
P—Kalium	4	4	0,18 mmol/L	
P—Klorid	2	2	-Ŧ	
P—Kolesterol	5	5	0,39 mmol/L	
P—Kreatinin	8	8	8,4 µmol/L	
P—Laktat	12	12	-Ŧ	
P—LD	12	12	0,50 µkat/L	
P-LDL-Kolesterol	12	12	0,64 mmol/L	



Equalis performance specifications ("quality goals")

Different specifications for individual results and groups of results (methods or "conglomerates")

Tabell 2. Hematologi. Kvalitetsmålet uppställt av Equa

pertgrupp för hematologi.

Storhet	Maximal avvikelse för enskilt resultat från målvärde (±%)	Maximal avvikelse för hel metodgrupp (metodbias) (±%)	Kommentar
B—Hemoglobin	5	2	
B—Leukocyter	15	6	
B—EVF	5	2	
B—Trombocyter	16	6	
B—Lymfocyter	16		
B—Granulocyter	23		
B-MCV	3	1	
B—Erytrocyter	5	2	



Different quality specifications due to different ways to calculate them?

	Equalis	Labquality	RCPAQAP	Rili-bäk
P-Albumin	5 %	5 %	6 %	20 %
P-Calcium	3 %	3 %	4 %	10 %
P-Phosphate	6 %	6 %	8 %	16 %
P-Chloride	2 %	2 %	3 %	8 %
P-Creatinine	8 %	8 %	8 %	20 %
P-Cholesterol	5 %	5 %	6 %	13 %
B-Haemoglobin	5 %	5 %		6 %
B-Leukocytes	15 %	10 %		18 %
HbA1c	7 % at 48 mmol/mol	8 %	8 %	18 %
P-CRP	10 % (hosp) 15 % (POCT)	15 %		20 %
Erc-MCV	3 %	5 %		
	EQUALIS			

A complex matter


For each measurand:


Quality specification x number of intended uses x number of EQA-materials x number of calculation models x etc x


We need a simple model....





valitetsmål (%): gen rapportgrupp:	+/- 15 Sysmex				
		Egen rapportgrup	op (148)	Samtliga (241)	
Eget resultat:	5,44	Medelvärde:	5,24	Medelvärde:	5,20
		SD:	0,17	SD:	0,19
Åsatt värde:		CV%:	3,2	CV%:	3,7
		Egen avvikelse		Egen avvikelse	
		Absolut (enheter):	+0,2	Absolut (enheter):	+0,24
		Relativ (%):	+3,8	Relativ (%):	+4,5
		Antal SD	+1,20	Antal SD	+1,23
		Medelavvikelse%:	+1,58	Medelavvikelse%:	+2,29
		(senaste 10 omgångan	na)	(senaste 10 omgångarn	a)
















P-Kreatinin (μ mol/L)

Kvalitetsmål (%): +/- 8 Egen rapportgrupp: Siemens enzymatisk

	-gennappengrapp.	j					
			Egen rapportgrupp (18)		Samtliga (102)		
(Eget resultat:	61	Medelvärde:	61,6	Medelvärde:	65,4	
	-		SD:	1,05	SD:	3,62	
	Åsatt värde:		CV%:	1,7	CV%:	5,5	
			Egen avvikelse		Egen avvikelse		
			Absolut (enheter):	-0,6	Absolut (enheter):	-4,43	
			Relativ (%):	-1,0	Relativ (%):	-6,8	
			Antal SD	-0,57	Antal SD	-1,22	
			Medelavvikelse%:	-1,83	Medelavvikelse%:	-6,97	
$\overline{)}$			(senaste 10 omgångar	ma)	(senaste 10 omgångarna	a)	




A transition from Jaffe to enzymatic methods in Sweden






Improved performance over years



The last 4 years: the fraction of creatinine results within performance specification (+/- 8 %) has declined






AJCTML recognized RMP!

Performance specifications has been agreed with the professional societes in Sweden for three different intended uses:

Comparison method:

Diagnostic method:

Monitoring method:



±15 % från en jämförelsemetods resultat.

valitetsnivån ska uppnås vid glukosmätning i sjukvården, samt vid egenmätning av patienter själva, för uppföljning av patienter med känd diabetes. Denna kvalitetsnivå motsvarar ISO 15197:2013. Vissa undantag finns, se silvernivån.

Definition of the measurand.

- 1) The component or analyte is easy to defind: glucose
- 2) The measurand: the concentration of glucose in the patients blood plasma

Practical advice to laboratories and manufacturers on how to verify their methods

- 1) Step 1: Verify that the selected comparison method fulfills 'gold criteria': TEa 7%, including preanalytical errors and sample specific errors.
- 2) Step 2: Compare your working method with the comparison method.

95% of the results should be within +/-10% of the comparison method (silver criteria) or +/-15% (bronze criteria)



The total allowable error should also consider **preanalytical errors** and the '**matrix effect**' ('sample specific errors')

5.3. Resultatets osäkerhet

Mätrutinens totalfel kan beräknas med följande formel för både venösa och kapillära prover:

 $Totalfelet = \pm 1,64 \times \sqrt{imprecision^2 + matriseffekt^2 + preanalytiskt slumpfel^2 + |bias|}$

Totalfelet får alltså vara högst ±10 % om kvalitetsmålet ska anses vara uppfyllt. Observera dock att matriseffekt samt preanalytiskt fel är svårkvantifierade.



AJCTML recognized RMP! Performance specifications has been agreed with the professional societes in Sweden for three different intended uses: Jämförelsemetod: 95 % av glukosresultaten ska vara inom ±7 % från resultaten med en referensmetod. Comparison method: Kvalitetsnivan behö ISO15197 recognize när man använder meto metoder. also YSI as a Diabetesdiagnostik: 95 % av glu reference method jämförelsemetods resultat. Med k denna kvalitetsnivå uppnås på sju for Plasma-Glucose. Diagnostic method: Kvalitetsnivan sto uppnas vid dia uatio gränsområde och i a patienter med kontinuerlig egenmataren används för kalibrering av CGM och patienter behöva egenmätare Diabetesuppföljnin If a meter fulfils criteria for ±15 % från en jämfö Monitoring method: accuracy in relation to valitetsnivan ska ut av patienter själva, f YSI, does it also fulfil the kvalitetsnivå motsvar Silver criteria?



The summary

Quality specifications might be useful

Different specifications according to the intended use, sample material used, etc, make the situation very complicated.

A simplified model must be used to reduce the number <u>of possible</u> <u>specifications</u> to a number of <u>needed specifications</u>

A hard work to underpin specifications







Take a home message

Performance specifications for test results are needed, simply in order to evaluate if results from a test method fulfils them or not.

Different performance specifications might be needed according to the intended use of a test and according to which method that is being used to specify the quality of the test results..

The number of <u>possible</u> performance specifications need to be restricted to a number of <u>needed</u> performance specifications.

Quality specifications should be based on one of the three models; clinical evidence, biological variation and state-of-the-art. The EFLM Task and finish group "Allocation of laboratory tests to different models for performance specifications" (TFG-DM) will discuss how the three models should be implemented for different measurands and various intended uses of the test results.

